Latest / This Week In Medicine
NEJM August 2026 Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
This clinical study investigates the effectiveness of selpercatinib, a targeted drug that blocks the RET protein, as a follow-up treatment for patients with early-stage lung cancer who have already undergone surgery or radiation. Researchers conducted a rigorous trial comparing this medication to a placebo to determine if it could prevent the disease from returning in patients with specific genetic markers. The findings demonstrate that selpercatinib significantly extends event-free survival, drastically reducing the likelihood of cancer recurrence or death compared to those who did not…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.